Key result
Adding bevacizumab to paclitaxel linked to ~132% higher risk of Grade 2+ peripheral neuropathy.
Why the study?
The potential exacerbation of paclitaxel-induced neuropathy by concurrent bevacizumab use in breast cancer patients was uncertain.
Does concurrent use of bevacizumab exacerbate paclitaxel-induced neuropathy in female patients with breast cancer?
Cohort (n=107)
Yes
Does concurrent use of bevacizumab exacerbate paclitaxel-induced neuropathy in female patients with breast cancer?
Concurrent use of bevacizumab with paclitaxel significantly increases the risk and severity of peripheral sensory neuropathy in breast cancer patients.
Answers are grounded in this paper and cite their sources.
May warrant neuropathy surveillance with bevacizumab-paclitaxel; leaves open causality and needs randomized confirmation.
BACKGROUND: Bevacizumab (BEV), a humanized anti-vascular endothelial growth factor (VEGF) monoclonal antibody, enhances the antitumor effectiveness of paclitaxel (PTX)-based chemotherapy in many metastatic cancers. A recent study in mice showed that VEGF receptor inhibitors can interfere with the neuroprotective effects of endogenous VEGF, potentially triggering the exacerbation of PTX-induced neuropathy. In clinical trials, exacerbation of neuropathy in patients who received PTX combined with BEV (PTX+BEV) has generally been explained by increased exposure to PTX owing to the extended duration of chemotherapy. We investigated whether the concurrent use of BEV is associated with the exacerbation of PTX-induced neuropathy. METHODS: Female patients with breast cancer who had received weekly PTX or PTX+BEV from September 2011 through May 2016 were studied retrospectively. PTX-induced neuropathy was evaluated at the same time points (at the 6th and 12th courses of chemotherapy) in both cohorts. A multivariate Cox proportional-hazards model was used to assess the independent effect of BEV on the time to the onset of neuropathy. RESULTS: A total of 107 patients (median age, 55 years; range, 32-83) were studied. Sixty-one patients received PTX as adjuvant chemotherapy, 23 received PTX for metastatic disease, and 23 received PTX+BEV for metastatic disease. Peripheral sensory neuropathy was worse in patients who received PTX+BEV than in those who received PTX alone: at the 6th course, Grade 0/1/2/3 = 4/13/4/0 vs. 25/42/6/0 (P = 0.095); at the 12th course, 2/3/11/3 vs. 7/30/23/2 (P = 0.016). At the 12th course, the incidence of Grade 2 or higher neuropathy was significantly higher in patients treated with PTX+BEV than in those treated with PTX alone (74% vs. 40%; P = 0.017). In multivariate analysis, BEV was significantly associated with an increased risk of neuropathy (HR 2.32, 95% CI 1.21-4.44, P = 0.012). CONCLUSIONS: The concurrent use of BEV could worsen PTX-induced neuropathy in patients with breast cancer.
No takes yet. Share an insight, caveat, or question.
Matsuoka et al. (2016) conducted a cohort in Breast cancer (n=107). Bevacizumab combined with paclitaxel vs. Paclitaxel alone was evaluated on Time to the onset of Grade 2 or higher peripheral sensory neuropathy (HR 2.32, 95% CI 1.21-4.44, p=0.012).
Synapse has enriched 10 related papers. Consider them for comparative context: